Please login to the form below

Not currently logged in
Email:
Password:

cervical cancer

This page shows the latest cervical cancer news and features for those working in and with pharma, biotech and healthcare.

Iovance up on good ASCO abstract data for cervical cancer therapy

Iovance up on good ASCO abstract data for cervical cancer therapy

The headline news is data from the cervical cancer trial of LN-145, which revealed an overall response rate (ORR) of 44% in recurrent cervical cancer, with 89% of patients showing ... That compares very well with results seen with Merck &Co’s PD-1

Latest news

  • Advaxis shaken by another FDA hold on cervical cancer vaccine Advaxis shaken by another FDA hold on cervical cancer vaccine

    Suspends enrolment into pivotal phase 3 trial. Advaxis shares have fallen after the FDA placed a partial hold on its lead cancer vaccine axalimogene filolisbac (Axal). ... One of those trials involved a combination of Axal with AstraZeneca’s PD-L1

  • Artificial intelligence in healthcare Artificial intelligence in healthcare

    AI is already being used to identify women whose Twitter posts indicate may have increased risk of developing ovarian and cervical cancer, and earlier this year the UK launched a project ... The aim is to spot at least 50, 000 cases of prostate, ovarian,

  • Sanofi’s latecomer PD-1 gets date for FDA verdict Sanofi’s latecomer PD-1 gets date for FDA verdict

    cancer (NSCLC), an indication which is fast becoming the main battleground for the PD-1/PD-L1 class and at the moment is dominated by Keytruda. ... which none of the first five PD-1/PD-L1 drugs have been approved, as well as cervical cancer.

  • Sanofi/Regeneron start first filings for PD-1 drug cemiplimab Sanofi/Regeneron start first filings for PD-1 drug cemiplimab

    The company plans to have pivotal trials ongoing in first-line NSCLC, second-line cervical cancer and advanced basal cell carcinoma - another form of skin cancer - in 2018, along with ... While cervical cancer and BCC are still an untapped marketed for

  • Boehringer says Avastin biosimilar on track as Phase III gets underway Boehringer says Avastin biosimilar on track as Phase III gets underway

    Clinical data suggests candidate has same biologic profile as Roche’s cancer drug. ... Boehringer Ingelheim says it has clinical data in hand that show its biosimilar version of Roche's cancer blockbuster Avastin is bioequivalent to the brand.

More from news
Approximately 9 fully matching, plus 141 partially matching documents found.

Latest Intelligence

  • 2019: CRISPR and therapeutic gene editing comes of age 2019: CRISPR and therapeutic gene editing comes of age

    hope was that - without the brake of PD-1 – the edited cells would attack and defeat the cancer. ... The approach is however also set to be tested as an in vivo therapy for cervical cancer caused by human papillomavirus (HPV) by researchers in China,

  • AI’s potential in the pharma life cycle AI’s potential in the pharma life cycle

    Proactive intervention. Already AI is being used to identify women whose Twitter posts indicate they may have increased risk of developing two relatively rare diseases: ovarian cancer and cervical cancer.

  • Immunisation politicised Immunisation politicised

    human papilloma virus (HPV), including strains that lead to cervical cancer. ... Practitioners were concerned that a hasty introduction of the vaccine would lead to lower participation rates in cervical cancer screening programmes using the pap smear test

  • Pharma deals in August 2015 Pharma deals in August 2015

    Immuno-oncology combinations in lung cancer. Not disclosed. Peregrine Pharmaceuticals. Combination clinical trials. ... Acquisition ‐ company. 847. Inovio. AZ/Medimmune. INO‐3112 vaccine in P1/2 for cervical and head &neck cancer.

  • Country report: The healthcare market in Brazil Country report: The healthcare market in Brazil

    In September 2011, the government announced the funding of programmes that prevent, diagnose and treat cervical and breast cancer. ... AIDS, cancer, diabetes and less common conditions such as Chagas disease and endometriosis, covering around 400, 000

More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.

Latest appointments

  • Merck appoints new senior vice president Merck appoints new senior vice president

    Radvanyi will focus on leading the discovery of oncology therapies that leverage the natural ability of the body's immune system to fight cancer, as well as identifying biomarkers with the ... indications including lung, cervical and breast cancer.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 1 fully matching, plus 6 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
PRMA Consulting Ltd

PRMA Consulting is an independent consultancy solving some of the most challenging pricing, reimbursement and market access issues facing international...

Latest intelligence

What are you doing, Dave?
Artificial Intelligence (AI) is invading all areas of healthcare. Is it our saviour or our nemesis?...
Fake News is Bad for your Health
Ill informed patients make poor health decisions...
Secrets of Pharma Advertising
If the goal of branding is to be different, why do so many Pharma brand ads look the same?...

Infographics